Forest rides Namenda growth wave past analysts' earnings estimates

Forest Laboratories ($FRX) handily beat analyst expectations with Q3 earnings of 36 cents per share, on unexpectedly strong sales of its Alzheimer's disease drug Namenda and brand-new antidepressant Viibryd. New CEO Brent Saunders said he's looking at rejigging the company's strategy to prepare for Namenda's patent expiration in 2015. Report